Skip to main content

Targeting Lipids for Cardiovascular Health: Novel Mechanisms and Therapeutics

Guest edited by Dr. Felice Gragnano, Dr. Arturo Cesaro, and Prof. Paolo Calabrò from the University of Campania “Luigi Vanvitelli”, Caserta, Italy

New Content ItemLipids in Health and Disease invites you to contribute a manuscript to our new thematic series, "Targeting Lipids for Cardiovascular Health: Novel Mechanisms and Therapeutics". 

People who maintain ideal cardiovascular health have high life expectancy and low lifetime risk of disabling and life-threatening medical conditions. Therefore, the identification and adoption of novel strategies to pursue ideal cardiovascular health represent a vital opportunity to improve the prevention and treatment of cardiovascular diseases. Because atherogenic lipids and lipoproteins play a causal role in the initiation and progression of endothelial dysfunction and atherosclerosis, maintenance of optimal lipid levels is necessary to attain ideal cardiovascular health status.

Evidence from Mendelian randomization studies and randomized trials has conclusively demonstrated that lower low-density lipoprotein cholesterol (LDL-C) can effectively reduce cardiovascular risks. Additional benefits may derive from lowering triglycerides and lipoprotein(a) and elevating serum levels and activity of high-density lipoprotein cholesterol (HDL-C).

To date, numerous challenges and controversies exist concerning the cumulative effect of lipid-carrying lipoproteins on cardiovascular health, the magnitude of the clinical benefit obtained by achieving and maintaining optimal lipid levels and the best timing to initiate lipid-modifying strategies to mitigate cardiovascular risk.

We invite you to contribute to this new thematic series of Lipids in Health and Disease, which will focus on the link between lipids and cardiovascular health from mechanisms to therapeutics, emphasizing the importance of an individualized approach in clinical and preclinical studies design (so-called “precision medicine”).

We warmly welcome articles, including original research, narrative reviews, systematic reviews and meta-analyses, mini-reviews, and commentary on this relevant and rapidly evolving topic.

Keywords:

Lipids, lipoproteins, LDL, HDL, lipoprotein(a), triglycerides, atherosclerosis, endothelial dysfunction, cardiovascular disease, cardiometabolic disease.

All submissions should be made by 31 December 2023.

Topics:

  • Mechanisms and molecular pathways affecting lipids and lipoproteins metabolism
  • Impact of genetics on lipid and metabolic disorders
  • Effect of lipid-lowering therapy on cardiovascular health
  • Lipid targets in cardiovascular disease
  • Future perspective and novel therapeutic strategies in dyslipidemias

Questions to be answered:

  • What are the novel mechanisms involved in the regulation of lipid metabolism?
  • Can genetic evaluation guide decision-making in the management of lipid disorders?
  • Should lipid targets be individualized according to patient risk profile?
  • What is the mechanistic link between cholesterol and triglyceride disorders?
  • How do non-LDL cholesterol targets affect clinicians’ decisions in contemporary practice?
  • What are the following steps to be taken to reduce the residual cardiovascular burden?

This collection of articles has not been sponsored and articles have undergone the journal’s standard peer-review process.

Please find out more about our journal and its policies, here. Submission guidelines can be found here, and please submit to the series via our submission system.


  2. Oxylipins, the oxidative metabolites of polyunsaturated fatty acids (PUFAs), serve as key mediators of oxidative stress, inflammatory responses, and vasoactive reactions in vivo. Our previous work has establis...

    Authors: Tong Liu, Inci Dogan, Michael Rothe, Evgenij Potapov, Felix Schoenrath, Maik Gollasch, Friedrich C. Luft and Benjamin Gollasch
    Citation: Lipids in Health and Disease 2023 22:138
    Content type: Research Published on:

  3. Accumulating evidence indicated that apolipoprotein B (apoB) was the principal lipid determinant of coronary artery disease (CAD). Nevertheless, the connection between apoB and angiographic progression of CAD ...

    Authors: Xing Shui, Zheqi Wen, Ruimin Dong, Zefeng Chen, Leile Tang, Wenyu Tang, Zhen Wu and Lin Chen
    Citation: Lipids in Health and Disease 2023 22:125
    Content type: Research Published on:

  4. Patients with multi-vessel coronary artery disease (MV-CAD) have poorer clinical outcomes than those with single-vessel coronary artery disease (SV-CAD). Solid evidence underlines that high-density lipoprotein...

    Authors: Jiaqi Chen, Kangxiang Wu, Wanchun Cao, Jianan Shao and Mingyuan Huang
    Citation: Lipids in Health and Disease 2023 22:121
    Content type: Research Published on:

  5. Generally, low-density lipoprotein (LDL) particle size can be inferred from the LDL cholesterol concentration to total apolipoprotein B concentration ratio (LDL-C/ApoB ratio, hereinafter called LAR), which is ...

    Authors: Li Xiao, Kerui Zhang, Fang Wang, Min Wang, Qingxia Huang, Chenchen Wei and Zhongshan Gou
    Citation: Lipids in Health and Disease 2023 22:104
    Content type: Research Published on:

  6. A lthough the triglyceride-glucose (TyG) index has been shown to closely correlate with cardiometabolic outcomes and predict cardiovascular events in many groups, it remains unclear whether obese status in you...

    Authors: Weihua Chen, Shan Ding, Jiabin Tu, Guitao Xiao, Kaihong Chen, Yanbin Zhang, Rongchong Huang and Ying Liao
    Citation: Lipids in Health and Disease 2023 22:65
    Content type: Research Published on:

  7. The challenging rigorous management of hypercholesterolemia promotes referral to specialized units. This study explored the need, based on referral rate and cardiovascular (CV) risk factor control in patients ...

    Authors: Enric Serra-Planas
    Citation: Lipids in Health and Disease 2023 22:62
    Content type: Research Published on:

  8. Coronary artery calcification (CAC) is a potential risk marker of coronary atherosclerosis that has high specificity and sensitivity. However, the association between high-density lipoprotein cholesterol (HDL-...

    Authors: Farshad Abedi, Masoumeh Sadeghi, Navid Omidkhoda, Theodoros Kelesidis, Javad Ramezani, Sara Samadi and Amir Hooshang Mohammadpour
    Citation: Lipids in Health and Disease 2023 22:60
    Content type: Research Published on:

  9. The long-term excessive intake of exogenous cholesterol can lead to abnormally elevated blood lipid levels and induce cardiovascular and cerebrovascular diseases. However, the influence and relevance of exogen...

    Authors: Xichao Yu, Xue Ding, Han Feng, Yunhui Bi, Yu Li, Jinjun Shan and Huimin Bian
    Citation: Lipids in Health and Disease 2023 22:51
    Content type: Research Published on:

  10. High serum NEFA and GDF-15 are risk factors for CAD and have been linked to detrimental cardiovascular events. It has been hypothesized that hyperuricemia causes CAD via the oxidative metabolism and inflammati...

    Authors: Jingru Cheng, Yongnan Lyu, Yufeng Mei, Qian Chen, Hang Liu and Yan Li
    Citation: Lipids in Health and Disease 2023 22:31
    Content type: Research Published on: